Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial
Luke K. Bolt1, G. Paul Amminger2,3,4, John Farhall1, Patrick D. McGorry2,3, Barnaby Nelson2,3, Connie Markulev5,3, Hok Pan Yuen2,3, Miriam R. Schäfer2,4, Nilufar Mossaheb4, Monika Schlögelhofer4, Stefan Smesny6, Ian B. Hickie7, Gregor Emanuel Berger8, Eric Y.H. Chen9, Lieuwe de Haan10, Dorien H. Nieman10, Merete Nordentoft11, Anita Riecher-Rössler12, Swapna Verma13, Andrew Thompson2,14,15
1Department of Psychology and Counselling, La Trobe University, Bundoora, Australia
2Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Australia
3The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia
4Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria
5Orygen - The National Centre of Excellence in Youth Mental Health, Parkville, Australia
6Department of Psychiatry, University Hospital Jena, Jena, Germany
7Brain and Mind Centre, University of Sydney, Sydney, Australia
8Child and Adolescent Psychiatric Service of the Canton of Zurich, Zurich, Switzerland
9Department of Psychiatry, University of Hong Kong, Hong Kong
10Department of Psychiatry, Amsterdam University Medical Centers, the Netherlands
11Psychiatric Centre Bispebjerg, Copenhagen, Denmark
12Psychiatric University Clinics Basel, Basel, Switzerland
13Institute of Mental Health, Singapore, Singapore
14Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, England, United Kingdom of Great Britain and Northern Ireland
15North Warwickshire Early Intervention in Psychosis Service, Coventry and Warwickshire National Health Service Partnership Trust, Coventry, England, United Kingdom of Great Britain and Northern Ireland
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Schizophrenia Research
Tập 206
67-74
Thông tin tác giả